SNYNF:OTO-Sanofi (USD)

COMMON STOCK | Drug Manufacturers - General | OTC Pink

Last Closing

USD 100

Change

0.00 (0.00)%

Market Cap

USD 112.02B

Volume

2.85K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 240.18B
NVSEF Novartis AG

N/A

USD 208.10B
RHHBY Roche Holding Ltd ADR

N/A

USD 202.85B
RHHBF Roche Holding AG

N/A

USD 202.85B
RHHVF Roche Holding AG Participation

N/A

USD 202.50B
GLAXF GSK plc

N/A

USD 92.19B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 66.43B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 66.43B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 53.36B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 52.77B

ETFs Containing SNYNF

SEUC:PA SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

N/A

USD 1.27B
SYBD:F SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

N/A

USD 1.27B
SYBD:XETRA SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

N/A

USD 1.27B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.39% 73% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.39% 71% C- 50% F
Trailing 12 Months  
Capital Gain -9.46% 54% F 52% F
Dividend Return 3.50% 76% C+ 47% F
Total Return -5.96% 56% F 53% F
Trailing 5 Years  
Capital Gain 19.55% 78% C+ 73% C
Dividend Return 21.22% 93% A 68% D+
Total Return 40.77% 78% C+ 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 3.40% 65% D 46% F
Dividend Return 7.11% 53% F 47% F
Total Return 3.71% 59% D- 64% D
Risk Return Profile  
Volatility (Standard Deviation) 12.64% 97% N/A 95% A
Risk Adjusted Return 56.29% 91% A- 90% A-
Market Capitalization 112.02B 86% B+ 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector